Latest & greatest articles for finasteride

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on finasteride or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on finasteride and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for finasteride

1. Finasteride

Finasteride Top results for finasteride - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for finasteride The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

2. Finasteride: rare reports of depression and suicidal thoughts

Finasteride: rare reports of depression and suicidal thoughts Finasteride: rare reports of depression and suicidal thoughts - GOV.UK GOV.UK uses cookies to make the site simpler. Search Finasteride: rare reports of depression and suicidal thoughts We have received reports of depression and, in rare cases, suicidal thoughts in men taking finasteride 1 mg (Propecia) for male pattern hair loss. Be aware that depression is also associated with finasteride 5 mg (Proscar). Published 24 May 2017 From (...) : Therapeutic area: , , Contents Advice for healthcare professionals: since finasteride has been marketed there have been a number of spontaneous adverse drug reaction reports suggesting a possible link to depression, and in rare cases, suicidal thoughts advise patients to stop finasteride 1 mg (Propecia) immediately if they develop depression and inform a healthcare professional be aware that the product information for finasteride 5 mg (Proscar) already lists depression as a possible adverse reaction

2017 MHRA Drug Safety Update

3. Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety

Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2014 Authors' conclusions Four systematic reviews and six randomized controlled trials were found regarding the clinical effectiveness and safety of dutasteride and finasteride compared to each other or placebo

2014 Health Technology Assessment (HTA) Database.

4. Dutasteride and Finasteride for Men with Benign Prostatic Hyperplasia

Dutasteride and Finasteride for Men with Benign Prostatic Hyperplasia TITLE: Dutasteride and Finasteride for Men with Benign Prostatic Hyperplasia: Comparative Clinical Effectiveness and Safety DATE: 07 March 2014 RESEARCH QUESTIONS 1. What is the comparative clinical effectiveness and safety of dutasteride and finasteride for men with benign prostatic hyperplasia? 2. What is the clinical effectiveness and safety of dutasteride versus placebo for men with benign prostatic hyperplasia? 3. What (...) is the clinical effectiveness and safety of finasteride versus placebo for men with benign prostatic hyperplasia? KEY MESSAGE Four systematic reviews and six randomized controlled trials were found regarding the clinical effectiveness and safety of dutasteride and finasteride compared to each other or placebo for the treatment of benign prostatic hyperplasia. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 2), University of York Centre

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer

Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer Reed SD, Scales CD, Stewart SB, Sun J, Moul JW, Schulman KA, Xu J Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of chemoprevention of prostate cancer using finasteride, compared with no chemoprevention, considering risk groups. At a threshold of 100,000 US dollars per quality-adjusted life

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

6. Finasteride for benign prostatic hyperplasia. (PubMed)

Finasteride for benign prostatic hyperplasia. Benign prostatic hyperplasia (BPH), a non-malignant enlargement of the prostate in aging men, can cause bothersome urinary symptoms (intermittency, weak stream, straining, urgency, frequency, incomplete emptying). Finasteride, a five-alpha reductase inhibitor (5ARI), blocks the conversion of testosterone to dihydrotestosterone, reduces prostate size, and is commonly used to treat symptoms associated with BPH.To compare the clinical effectiveness (...) and harms of finasteride versus placebo and active controls in the treatment of lower urinary tract symptoms (LUTS).We searched The Cochrane Library (which includes CDSR (Cochrane Database of Systematic Reviews), DARE (Database of Abstracts of Reviews of Effects), HTA (Heath Technology Assessments), and CENTRAL (Cochrane Central Register of Controlled Trials, and which includes EMBASE and MEDLINE), LILACS (Latin American and Caribbean Center on Health Sciences Information) and Google Scholar

2010 Cochrane

7. Outcomes Associated With the Use of Finasteride: An Evaluation of this Medication as a Chemoprotective Agent and its Efficacy

Outcomes Associated With the Use of Finasteride: An Evaluation of this Medication as a Chemoprotective Agent and its Efficacy "Outcomes Associated With the Use of Finasteride: An Evaluation of this" by Catherine H. Cieslik < > > > > > Title Author Date of Graduation 8-14-2010 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Latha Reddy Second Advisor Annjanette Sommers MS, PAC Third Advisor Rob Rosenow PharmD, OD Rights . Abstract (...) Background: Whether a male should be placed on a well-studied pharmaceutical agent thought to have chemoprotective properties, is currently a question that is debated by clinicians. The purpose of this study is to determine the benefits versus harms associated with finasteride as a chemoprotective agent. Finasteride, has been used for the treatment of benign prostatic hyperplasia. It has been hypothesized that, since this medication resulted in the reduction of PSA levels, and a decrease in the size

2010 Pacific University EBM Capstone Project

8. Finasteride: potential risk of male breast cancer

Finasteride: potential risk of male breast cancer Finasteride: potential risk of male breast cancer - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Finasteride: potential risk of male breast cancer Patients should be advised to promptly report to their doctor any changes in their breast tissue such as lumps, pain, or nipple discharge. Published 11 December 2014 From: Therapeutic area: , Article date: December 2009 Finasteride is an inhibitor of type II 5α-reductase, an enzyme (...) that metabolises testosterone into the more potent androgen, dihydrotestosterone (DHT), resulting in a reduction in DHT concentrations in serum and target tissues. 5 mg finasteride (Proscar) is used for the treatment and control of benign prostatic hyperplasia because enlargement of the prostate gland is dependent on conversion of testosterone to DHT. Finasteride can also reduce scalp and serum DHT concentrations, and the 1 mg dose (Propecia) is indicated for the treatment of men with androgenetic alopecia

2010 MHRA Drug Safety Update

9. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer

Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer Zeliadt S B, Etzioni R D, Penson D F, Thompson I M, Ramsey S D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of the 5-alpha-reductase inhibitor finasteride (5 mg/day) for the prevention of prostate cancer. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population The model analysed data for a hypothetical cohort of men aged 55 years who commenced

2005 NHS Economic Evaluation Database.

10. Finasteride reduced prostate cancer but led to more high grade tumours and sexual side effects

Finasteride reduced prostate cancer but led to more high grade tumours and sexual side effects Finasteride reduced prostate cancer but led to more high grade tumours and sexual side effects | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Finasteride reduced prostate cancer but led to more high grade tumours and sexual side effects Article Text Therapeutics Finasteride reduced prostate cancer but led to more high grade tumours

Full Text available with Trip Pro

2004 Evidence-Based Medicine (Requires free registration)

11. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia

An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia McDonald H, Hux M, Brisson M, Bernard L, Nickel J C Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined finasteride (FIN), a 5-alpha-reductase inhibitor, either alone or in combination with doxazosin (DOX), an alpha-blocker, for the treatment of benign prostate hyperplasia (BPH). The doses used were 5 mg FIN once daily and 4 mg DOX once daily. Type

2004 NHS Economic Evaluation Database.

12. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. (PubMed)

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alpha-reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown.We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving 3047 men to compare the effects (...) of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia.The risk of overall clinical progression--defined as an increase above base line of at least 4 points in the American Urological Association symptom score, acute urinary retention, urinary incontinence, renal insufficiency, or recurrent urinary tract infection--was significantly reduced by doxazosin (39 percent risk reduction, P<0.001) and finasteride (34 percent risk

2003 NEJM

13. The influence of finasteride on the development of prostate cancer. (PubMed)

The influence of finasteride on the development of prostate cancer. Androgens are involved in the development of prostate cancer. Finasteride, an inhibitor of 5alpha-reductase, inhibits the conversion of testosterone to dihydrotestosterone, the primary androgen in the prostate, and may reduce the risk of prostate cancer.In the Prostate Cancer Prevention Trial, we randomly assigned 18,882 men 55 years of age or older with a normal digital rectal examination and a prostate-specific antigen (PSA (...) ) level of 3.0 ng per milliliter or lower to treatment with finasteride (5 mg per day) or placebo for seven years. Prostate biopsy was recommended if the annual PSA level, adjusted for the effect of finasteride, exceeded 4.0 ng per milliliter or if the digital rectal examination was abnormal. It was anticipated that 60 percent of participants would have prostate cancer diagnosed during the study or would undergo biopsy at the end of the study. The primary end point was the prevalence of prostate

2003 NEJM

14. Direct To Consumer Advertising: Finasteride for male pattern hair loss

Direct To Consumer Advertising: Finasteride for male pattern hair loss [40] Direct To Consumer Advertising: Finasteride for male pattern hair loss | Therapeutics Initiative Independent Healthcare Evidence > > [40] Direct To Consumer Advertising: Finasteride for male pattern hair loss Case: Mr. Jones (26 years old) comes in to see you about a cough he has had for 3-4 weeks. You’ve just finished listening to his chest and reassured him that it’s the aftermath of a viral infection. He asks you (...) ), finasteride (Propecia ® , $100 million) , sildenafil (Viagra ® , $94 million), omeprazole (Prilosec ® , $80 million), and orlistat (Xenical ® , $76 million). Sales The 25 top-selling DTCA drugs accounted for 40.7%, or $7.2 billion, of the overall $17.7 billion (19%) increase in drug sales (retail) in 1999 over 1998. Doctors wrote 34.2% more prescriptions in 1999 than in 1998 for the top 25 DTCA drugs. Doctors wrote only 5.1% more prescriptions for all other prescription drugs. What should clinicians do

2001 Therapeutics Letter

15. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia

Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia Wilde MI, Goa KL Authors' objectives To overview the pharmacology of finasteride and provide an update of its clinical effects in patients with benign prostatic hyperplasia. Searching MEDLINE, EMBASE (...) and AdisBase (a proprietary database of Adis International, Auckland, New Zealand) were searched for trials published in any language since 1966 until February 1999. Search terms included finasteride combined with either prostatic hypertrophy or benign prostatic hyperplasia. Bibliographic information, including contributory unpublished data was also requested from the company developing the drug. Study selection Study designs of evaluations included in the review Inclusion of studies was mainly based

1999 DARE.

16. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. (PubMed)

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the benefit is sustained and whether finasteride reduces the incidence of related events, including the need for surgery and the development of acute urinary retention (...) , is not known.In this double-blind, randomized, placebo-controlled trial, we studied 3040 men with moderate-to-severe urinary symptoms and enlarged prostate glands who were treated daily with 5 mg of finasteride or placebo for four years. Symptom scores (on a scale of 1 to 34), urinary flow rates, and the occurrence of outcome events were assessed every four months in 3016 men. Prostate volume was measured in a subgroup of the men. Complete data on outcomes were available for 2760 men.During the four-year

1998 NEJM

17. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. (PubMed)

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. Men with benign prostatic hyperplasia can be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen concentrations. However, the effects of the two types of drugs have not been compared.We compared the safety and efficacy (...) of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia. American Urological Association symptom scores and peak urinary-flow rates were determined at base line and periodically for one year.The mean changes from base line in the symptom scores in the placebo, finasteride, terazosin, and combination-therapy groups at one year were decreases of 2.6, 3.2, 6.1, and 6.2 points, respectively (P<0.001 for the comparisons

1996 NEJM

18. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia

An economic evaluation of finasteride for treatment of benign prostatic hyperplasia An economic evaluation of finasteride for treatment of benign prostatic hyperplasia An economic evaluation of finasteride for treatment of benign prostatic hyperplasia Baladi J F, Menon D, Otten N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using 5 alpha-reductase inhibitor finasteride versus transurethral resection of the prostate (TURP), and watchful waiting (periodic monitoring of a patient by his physician, representing the "do nothing" option) in the treatment of patients (older men) with benign prostatic hyperplasia (BPH). Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis

1996 NHS Economic Evaluation Database.

19. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials Boyle P, Gould A L, Roehrborn C G Authors' objectives To examine whether (...) prostate size could predict the outcome of finasteride treatment, and therefore, indicate which men should be the best candidates for finsasteride therapy. Searching The authors do not provide details of the sources searched or the strategies employed. Study selection Study designs of evaluations included in the review Randomised, multicentre, placebo-controlled clinical trials of at least 12 months' duration were included. Specific interventions included in the review Terazosin, finasteride (5 mg

1996 DARE.

20. Finasteride: clinical and economic impacts

Finasteride: clinical and economic impacts Finasteride: clinical and economic impacts Finasteride: clinical and economic impacts Otten N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A new medical treatment for benign (...) prostatic hypertrophy (BPH), finasteride, was compared with the two most common treatment options that is transurethral resection of the prostate (TURP) and watchful waiting, for patients with varying degrees of symptom severity. Type of intervention Treatment; secondary prevention. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population Males receiving either finasteride, TURP or watchful waiting for the treatment of BPH. Patients had either mild, moderate or severe

1996 NHS Economic Evaluation Database.